Beneficial and harmful outcomes of tocilizumab in severe COVID‐19: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Beneficial and harmful outcomes of tocilizumab in severe COVID‐19: A systematic review and meta‐analysis

Published:2021-10 Issue:11 Volume:41 Page:884-906
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Rubio‐Rivas Manuel¹^ORCID,Forero Carlos G.²,Mora‐Luján José María¹,Montero Abelardo¹,Formiga Francesc¹,Homs Narcís A.¹,Albà‐Albalate Joan¹,Sánchez Laura¹,Rello Jordi²³⁴,Corbella Xavier¹²

Affiliation:

1. Department of Internal Medicine Bellvitge University Hospital Bellvitge Biomedical Research Institute‐IDIBELL University of Barcelona Barcelona Spain

2. School of Medicine Universitat Internacional de Catalunya Barcelona Spain

3. Centro de Investigación Biomédica en Red (CIBERES) Instituto de Salud Carlos III Madrid Spain

4. CRIPS Vall d’Hebrón Institute of Research Barcelona Spain

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/phar.2627

Reference132 articles.

1. Tocilizumab for the treatment of non‐critical COVID‐19 pneumonia: an overview of the rationale and clinical evidence to date

2. Dexamethasone in Hospitalized Patients with Covid-19